Atrial Fibrillation in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Real-World Incidence, Management, and Outcomes.
作者信息
Boyle Thomas A, Reza Nosheen, Hyman Matthew, Supple Gregory, See Vincent Y, Marzolf Amy, Hornsby Nicole, de Feria Alejandro, Wang Teresa, Margulies Kenneth B, Owens Anjali Tiku, Frankel David S
机构信息
Cardiovascular Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Cardiovascular Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
出版信息
JACC Clin Electrophysiol. 2025 Feb;11(2):411-413. doi: 10.1016/j.jacep.2024.10.014. Epub 2024 Dec 4.
Abstract
摘要
相似文献
1
Atrial Fibrillation in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Real-World Incidence, Management, and Outcomes.接受马伐卡坦治疗梗阻性肥厚型心肌病患者的心房颤动：真实世界的发病率、管理及结局
JACC Clin Electrophysiol. 2025 Feb;11(2):411-413. doi: 10.1016/j.jacep.2024.10.014. Epub 2024 Dec 4.
2
Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population.在当代肥厚型梗阻性心肌病患者人群中，真实世界对马卡坦特的应用。
Eur J Heart Fail. 2024 Jan;26(1):59-64. doi: 10.1002/ejhf.3120. Epub 2024 Jan 2.
3
One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy.马伐卡坦治疗梗阻性肥厚型心肌病的一年真实世界经验及其生理效应
Front Cardiovasc Med. 2024 Aug 30;11:1429230. doi: 10.3389/fcvm.2024.1429230. eCollection 2024.
4
Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten.接受马伐卡坦治疗的梗阻性肥厚型心肌病患者中新发房颤的发生率。
Heart Rhythm. 2024 Oct;21(10):2065-2067. doi: 10.1016/j.hrthm.2024.04.055. Epub 2024 Apr 15.
5
Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.梗阻性肥厚型心肌病患者行室间隔减容术治疗：肌球蛋白抑制与左心室舒张功能——来自 VALOR-HCM 研究的结果。
Circ Cardiovasc Imaging. 2022 Dec;15(12):e014986. doi: 10.1161/CIRCIMAGING.122.014986. Epub 2022 Nov 6.
6
New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy.新时代：美伐他汀治疗梗阻性肥厚型心肌病。
Cardiovasc Hematol Agents Med Chem. 2023;21(2):78-83. doi: 10.2174/1871525721666221019095218.
7
Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM: Insights From the VALOR-HCM Trial.梗阻性肥厚型心肌病中与马伐卡坦相关的左心房功能随时间的变化：来自VALOR-HCM试验的见解
JACC Cardiovasc Imaging. 2025 Mar;18(3):251-262. doi: 10.1016/j.jcmg.2024.08.005. Epub 2024 Sep 2.
8
Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy.Mavacamten，一种用于梗阻性肥厚型心肌病的首创心脏肌球蛋白抑制剂。
Ann Pharmacother. 2023 Apr;57(4):489-502. doi: 10.1177/10600280221117812. Epub 2022 Aug 11.
9
Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial.马卡丹特治疗伴或不伴高血压的梗阻性肥厚型心肌病：EXPLORER-HCM 试验的事后分析。
JACC Heart Fail. 2024 Mar;12(3):567-579. doi: 10.1016/j.jchf.2023.07.030. Epub 2023 Oct 18.
10
Eighteen-Month Real-World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population.在一个种族多样化的人群中使用 Mavacamten 治疗梗阻性肥厚型心肌病的 18 个月真实世界经验。
J Am Heart Assoc. 2024 Aug 6;13(15):e034069. doi: 10.1161/JAHA.123.034069. Epub 2024 Jul 31.
本文引用的文献
1
Real-World Experience and 36-Week Outcomes of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten.马伐卡坦治疗有症状的梗阻性肥厚型心肌病患者的真实世界经验及36周结局
JACC Heart Fail. 2024 Jun;12(6):1123-1125. doi: 10.1016/j.jchf.2024.03.009. Epub 2024 Apr 7.
2
Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten.接受马伐卡坦治疗的梗阻性肥厚型心肌病患者中新发房颤的发生率。
Heart Rhythm. 2024 Oct;21(10):2065-2067. doi: 10.1016/j.hrthm.2024.04.055. Epub 2024 Apr 15.
3
Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy.梗阻性肥厚型心肌病患者行室间隔减少术的肌球蛋白抑制治疗。
J Am Coll Cardiol. 2022 Jul 12;80(2):95-108. doi: 10.1016/j.jacc.2022.04.048.
4
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病（EXPLORER-HCM）的随机、双盲、安慰剂对照、3 期临床试验
Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29.
5
Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.肥厚型心肌病中心房颤动：患病率、临床影响和管理。
Heart Fail Rev. 2019 Mar;24(2):189-197. doi: 10.1007/s10741-018-9752-6.
Zotero 插件